NASDAQ: BTMDBiote Corp Stock
$3.30-0.01 (-0.3%)
Updated Apr 17, 2025
BTMD Price
$3.30
Fair Value Price
N/A
Market Cap
$180.54M
52 Week Low
$3.04
52 Week High
$8.44
P/E
36.67x
P/B
-1.7x
P/S
1.07x
PEG
0.29x
Dividend Yield
N/A
Revenue
$197.19M
Earnings
$3.16M
Gross Margin
70.5%
Operating Margin
7.67%
Profit Margin
1.6%
Debt to Equity
-2.12
Operating Cash Flow
$45M
Beta
0.43
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BTMD Overview
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BTMD's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
B
BTMD
Ranked#5 of 42
Ranked#5 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.82 | A | |
| $12.51 | A | |
| $174.80 | A |
Be the first to know about important BTMD news, forecast changes, insider trades & much more!
BTMD News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BTMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BTMD ($3.30) is trading below its intrinsic value of $4.43, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BTMD is poor value based on its earnings relative to its share price (36.67x), compared to the US market average (27.98x)
P/E vs Market Valuation
BTMD is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more BTMD due diligence checks available for Premium users.
Valuation
BTMD fair value
Fair Value of BTMD stock based on Discounted Cash Flow (DCF)
Price
$3.30
Fair Value
$10.68
Undervalued by
69.11%
BTMD ($3.30) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BTMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
36.67x
Industry
14.77x
Market
27.98x
BTMD is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BTMD is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
BTMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.7x
Industry
4.22x
BTMD price to earnings growth (PEG)
For valuing profitable companies with growth potential
BTMD is good value based... subscribe to Premium to read more.
PEG Value Valuation
BTMD's financial health
Profit margin
Revenue
$49.8M
Net Income
$3.7M
Profit Margin
7.4%
BTMD's Earnings (EBIT) of $15.13M... subscribe to Premium to read more.
Interest Coverage Financials
BTMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$122.4M
Liabilities
$224.6M
Debt to equity
-2.12
BTMD's short-term assets ($68.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BTMD's long-term liabilities ($173.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BTMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BTMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$12.4M
Investing
-$1.3M
Financing
-$9.9M
BTMD's operating cash flow ($45.24M)... subscribe to Premium to read more.
Debt Coverage Financials
BTMD vs Medical Care Facility Stocks
Biote Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.